Company profile

Ticker
ENZ
Exchange
Website
CEO
Elazar Rabbani
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
132866202

ENZ stock data

(
)

Calendar

9 Jun 20
12 Jul 20
31 Jul 20

News

Company financial data Financial data

Quarter (USD) Apr 20 Jan 20 Oct 19 Jul 19
Revenue 16.9M 19.38M 20.21M 20.92M
Net income -9.86M -7.69M -7.65M -5.39M
Diluted EPS -0.21 -0.16 -0.16 -0.12
Net profit margin -58.33% -39.66% -37.85% -25.76%
Operating income -9.72M -8.01M -8.2M -5.67M
Net change in cash 2.91M -5.39M -3.25M -3.91M
Cash on hand 54.41M 51.5M 56.89M 60.15M
Cost of revenue 12.48M 13.58M 14.52M 14.58M
Annual (USD) Jul 19 Jul 18 Jul 17 Jul 16
Revenue 81.17M 101.01M 105.09M 102.77M
Net income 2.49M -10.32M -2.5M 45.29M
Diluted EPS 0.05 -0.22 -0.05 0.97
Net profit margin 3.07% -10.22% -2.38% 44.06%
Operating income 1.73M -12.16M -3.15M 46.85M
Net change in cash 105K -4.13M -3.61M 49.67M
Cash on hand 60.15M 60.04M 64.17M 67.78M
Cost of revenue 57.92M 60.39M 59.48M 42.86M

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
23 Apr 20 Perlysky Dov Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 258,679
23 Apr 20 Fischer Rebecca J. Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 83,333
23 Apr 20 Clemens Peter J Iv Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 98,333
23 Apr 20 Clemens Peter J Iv Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 83,333
23 Apr 20 Blank Fabian Stock Option (to acquire Common Stock) Common Stock Grant Aquire A No 2.65 83,333 220.83K 83,333
60.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 77 82 -6.1%
Opened positions 8 5 +60.0%
Closed positions 13 12 +8.3%
Increased positions 21 26 -19.2%
Reduced positions 28 23 +21.7%
13F shares
Current Prev Q Change
Total value 113.15M 112.19M +0.9%
Total shares 28.83M 32.22M -10.5%
Total puts 17.1K 0 NEW
Total calls 27K 0 NEW
Total put/call ratio 0.6
Largest owners
Shares Value Change
Harbert Fund Advisors 5.62M $14.22M 0.0%
Evermore Global Advisors 4.01M $10.14M 0.0%
BLK BlackRock 3.65M $9.23M -1.3%
Renaissance Technologies 3.31M $8.38M -1.2%
Vanguard 2.26M $5.71M +4.6%
Dimensional Fund Advisors 2.07M $5.23M -2.9%
Wellington Management 1.69M $4.27M -52.8%
Ariel Investments 870.08K $2.2M -9.9%
STT State Street 758.63K $1.92M -4.7%
Geode Capital Management 559.74K $1.42M +8.9%
Largest transactions
Shares Bought/sold Change
Wellington Management 1.69M -1.89M -52.8%
Fondren Management 0 -727K EXIT
Oxford Asset Management 0 -191.85K EXIT
MS Morgan Stanley 7.19K -134.54K -94.9%
Two Sigma Investments 0 -116.19K EXIT
Vanguard 2.26M +99.91K +4.6%
Ariel Investments 870.08K -95.51K -9.9%
Millennium Management 127.92K +89.67K +234.4%
Squarepoint Ops 0 -73.44K EXIT
Dimensional Fund Advisors 2.07M -61.84K -2.9%

Financial report summary

?
Competition
WaferGen Bio-systems
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Additionally, affiliated, aforementioned, agency, Aid, antibody, Article, assistance, augmenting, Authorization, back, began, broader, cancelation, cancellation, cancelled, chain, CHF, CMS, committed, comply, context, coordinated, Corona, covenant, creditor, curtailing, deemed, distancing, documentation, documented, driven, duration, eased, economy, eligibility, eligible, emergency, employee, en, EUA, evolving, exacerbate, expenditure, explained, failure, FDA, forecasted, forgiven, half, hamper, healthy, HHS, highly, Human, inter, invoiced, iv, knowledge, Krise, LDT, lessen, light, long, lost, magnitude, media, mentioned, moderated, national, noncompliance, outbreak, pandemic, passed, Paycheck, payroll, penalty, persist, personnel, power, PPP, prepaid, prolonged, publicly, purported, purpose, put, ratio, recessionary, recoverable, recovery, refinance, regulatory, remote, repaid, repay, replace, reprieve, rest, restore, safe, salary, satisfy, SBA, scope, sector, sequestration, serological, short, show, small, social, specimen, speed, spent, spread, strain, sum, supply, suspended, Suspending, suspension, Switzerland, target, technical, temporarily, theinter, thereunder, Trademark, tranche, travel, twenty, uncollateralized, unconditional, undetermined, unprecedented, unrecouped, usage, verified, voluntarily, waiver, week, withheld, workforce, worse
Removed: argument, final, gain, heard, international, monitored, procedural, PTAB, regularly, remand, reverse, twointer

Patents

APP
Utility
Sphingosine Kinase Type 1 Inhibitors and Uses Thereof
25 Jun 20
Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management.
GRANT
Utility
Methods and intermediates for synthesizing SK1-I
16 Jun 20
The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4′-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.
GRANT
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
9 Jun 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
GRANT
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
26 May 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
GRANT
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
12 May 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.